Related references
Note: Only part of the references are listed.Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2020)
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
Kian Huat Lim et al.
NATURE COMMUNICATIONS (2020)
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
Zhou Han et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Development of Antisense Oligonucleotide Gapmers for the Treatment of Huntington's Disease
Tejal Aslesh et al.
GAPMERS: Methods and Protocols (2020)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Treating Disease at the RNA Level with Oligonucleotides
Arthur A. Levin
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment
Michael J. Gait et al.
NUCLEIC ACID THERAPEUTICS (2019)
Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Jay S. Charleston et al.
NEUROLOGY (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Aptamer-based targeted therapy
Guizhi Zhu et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
Naoki Iwamoto et al.
NATURE BIOTECHNOLOGY (2017)
Targeting Therapeutic Oligonucleotides
Arthur A. Levin
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy
Yusuke Echigoya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Cell-Penetrating Peptides: From Basic Research to Clinics
Giulia Guidotti et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
Annemieke Aartsma-Rus et al.
NUCLEIC ACID THERAPEUTICS (2017)
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
Elizabeth J. Ackermann et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2016)
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Tsukasa Sugo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
Takeshi Kasuya et al.
Scientific Reports (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
Eveline P. van Poelgeest et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
Richard S. Geary et al.
CLINICAL PHARMACOKINETICS (2015)
Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies
J. Scharner et al.
GENE THERAPY (2015)
Oligonucleotide Therapies: The Past and the Present
Karin E. Lundin et al.
HUMAN GENE THERAPY (2015)
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments
Yoshiki Sekijima
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Cell-penetrating peptides: strategies for anticancer treatment
Drazen Raucher et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus
Julia M. Janssen et al.
VACCINE (2015)
Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
W. Brad Wan et al.
NUCLEIC ACIDS RESEARCH (2014)
Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides
Andrew D. Burdick et al.
NUCLEIC ACIDS RESEARCH (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Peptide Conjugation of 2′-O-methyl Phosphorothioate Antisense Oligonucleotides Enhances Cardiac Uptake and Exon Skipping in mdx Mice
Silvana M. G. Jirka et al.
NUCLEIC ACID THERAPEUTICS (2014)
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl-Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Frank Rigo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Mark J. Graham et al.
CIRCULATION RESEARCH (2013)
Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease
Robert S. Janssen et al.
VACCINE (2013)
Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-4018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age
William L. Heyward et al.
VACCINE (2013)
Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals
Gene Hung et al.
NUCLEIC ACID THERAPEUTICS (2013)
Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs
Pradeep S. Pallan et al.
CHEMICAL COMMUNICATIONS (2012)
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Ryszard Kole et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine
Benjamin P. Sablan et al.
VACCINE (2012)
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age
Scott A. Halperin et al.
VACCINE (2012)
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy Muscle Progress in Exon Skipping and Stop Codon Read Through
Eric P. Hoffman et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
Anne C. Goldberg et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice
HaiFang Yin et al.
MOLECULAR THERAPY (2011)
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
Yimin Hua et al.
NATURE (2011)
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
Erich Koller et al.
NUCLEIC ACIDS RESEARCH (2011)
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Marco A. Passini et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Stereocontrolled Solid-Phase Synthesis of Oligonucleoside H-Phosphonates by an Oxazaphospholidine Approach
Naoki Iwamoto et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2009)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Solid-Phase Synthesis of Stereoregular Oligodeoxyribonucleoside Phosphorothioates Using Bicyclic Oxazaphospholidine Derivatives as Monomer Units
Natsuhisa Oka et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice
Natee Jearawiriyapaisarn et al.
MOLECULAR THERAPY (2008)
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals
Jeffrey A. Martinson et al.
IMMUNOLOGY (2007)
Comparative analysis of antisense oligonucleotide sequences for targeted skipping of Exon 51 during dystrophin Pre-mRNA splicing in human muscle
V. Arechavala-Gomeza et al.
HUMAN GENE THERAPY (2007)
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze et al.
NUCLEIC ACIDS RESEARCH (2007)
Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults
SA Halperin et al.
VACCINE (2006)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Immunotherapeutic uses of CpG oligodeoxynucleotides
DM Klinman
NATURE REVIEWS IMMUNOLOGY (2004)
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
DJ Rader et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy
A Aartsma-Rus et al.
NEUROMUSCULAR DISORDERS (2002)
Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR:: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
M Feldkötter et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells
F Takeshita et al.
JOURNAL OF IMMUNOLOGY (2001)
Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs
D Verthelyi et al.
JOURNAL OF IMMUNOLOGY (2001)
Stereo-enriched phosphorothioate oligodeoxgnucleotides: Synthesis, biophysical and biological properties
D Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2000)
Share Paper
